Upon completion of YourPDX Functional Precision Oncology testing, the final clinical research study report will be sent directly to the treating oncologist, detailing the testing protocol used, drugs or combination therapies tested in the orthotopic patient-derived xenograft (O-PDX) mouse models, and therapeutic response of each group of mouse cohorts over time, measured in terms of tumor volume. It will also include before-and-after murine-scale MRI images of tumor size as well as detailed histology images of structural cellular changes observed during the study.
Should a cancer patient not respond to first-line treatment, develop resistance to a previously effective therapy, or experience recurrence after successful treatment, the treating oncologist may be armed with alternative therapeutic options for that individual with cancer.1-4
References: 1 Das Thakur, M., Salangsang, F., Landman, A. et al. Modelling Vemurafenib Resistance in Melanoma Reveals a Strategy to Forestall Drug Resistance. Nature. 2013; 494(7436): 251–255. 2 Walters DM, Stokes JB, Adair SJ, et al. Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens. PLoS One. 2013;8(10): e77065. 3 Killion JJ, Radinsky R, Fidler IJ. Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice. Cancer Metastasis Rev. 1998-1999;17(3):279–284.
2013;8(10): e77065. 4 Qiu W, Su GH. Development of Orthotopic Pancreatic Tumor Mouse Models. Mol Biol. 2013; 980: 215-223.